3-benzoyl-1,4-dihydro-6-ethyl-2-methyl-4-oxopyridine | 144291-67-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-benzoyl-1,4-dihydro-6-ethyl-2-methyl-4-oxopyridine
• 英文别名: 3-benzoyl-6-ethyl-2-methyl-4-oxo-1,4-dihydropyridine；3-benzoyl-6-ethyl-2-methyl-1H-pyridin-4-one
• CAS: 144291-67-8
• 化学式: C₁₅H₁₅NO₂
• 分子量: 241.29
• InChiKey: RULPOBFSAVYKQU-UHFFFAOYSA-N

物化性质

• 沸点：
  380.5±42.0 °C(Predicted)
• 密度：
  1.126±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-benzoyl-1,4-dihydro-6-ethyl-2-methyl-4-oxopyridine 在 三氯氧磷 、 碳酸氢钠 作用下， 以 水 为溶剂， 反应 8.0h， 生成 (4-chloro-6-ethyl-2-methyl-pyridin-3-yl)-phenyl-methanone
  参考文献：
  名称：

  WO2007/100295

  摘要：

  公开号：
• 作为产物：
  描述：

  3-amino-1-phenylbut-2-en-1-one 、 5-(1-hydroxypropylidene)-2,2-dimethyl-[1,3]dioxane-4,6-dione 在 methanol-dichloromethane 作用下， 反应 1.0h， 以to give 3-benzoyl-1,4-dihydro-6-ethyl-2-methyl-4-oxopyridine (0.95 g) as a solid, m.p. 203° C.的产率得到3-benzoyl-1,4-dihydro-6-ethyl-2-methyl-4-oxopyridine
  参考文献：
  名称：

  Pyridinyl compounds which are useful as angiotensin II antagonists

  摘要：

  该发明涉及公式I的药物有用化合物，其中R.sup.1，R.sup.2，R.sup.3，R.sup.4，R.sup.5，R.sup.6，R.sup.7，Rz，X和Z具有此处定义的各种含义，以及它们的非毒性盐和含有它们的药物组合物。这些新型化合物对于治疗高血压和充血性心力衰竭等病症具有价值。该发明还涉及制造这些新型化合物的过程以及在医疗治疗中使用这些化合物。

  公开号：

  US05236937A1

文献信息

• 1,6-naphthyridone derivatives having angiotensin II antagonist activity
  申请人：Imperial Chemical Industries PLC

  公开号：US05217976A1

  公开（公告）日：1993-06-08

  The invention concerns pharmaceutically useful compounds of the formula I, in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, Ra, Rb, A, X and Z have the various meanings defined herein, and their non-toxic salts, and pharmaceutical compositions containing them. The novel compounds are of value in treating conditions such as hypertension and congestive heart failure. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.

  这项发明涉及公式I中的药用化合物，其中R.sup.1、R.sup.2、R.sup.3、R.sup.4、Ra、Rb、A、X和Z具有本文中定义的各种含义，以及它们的无毒盐和含有它们的药物组合物。这些新化合物在治疗高血压和充血性心力衰竭等疾病方面具有价值。该发明还涉及新化合物的制造工艺以及这些化合物在医疗治疗中的应用。
• Pyridinyl compounds which are useful as angiotensin II antagonists
  申请人：Imperial Chemical Industries PLC

  公开号：US05236937A1

  公开（公告）日：1993-08-17

  The invention concerns pharmaceutically useful compounds of the formula I, in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, Rz, X and Z have the various meanings defined herein, and their non-toxic salts, and pharmaceutical compositions containing them. The novel compounds are of value in treating conditions such as hypertension and congestive heart failure. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment. ##STR1##

  这项发明涉及公式I中的药用化合物，其中R.sup.1、R.sup.2、R.sup.3、R.sup.4、R.sup.5、R.sup.6、R.sup.7、Rz、X和Z具有本文所定义的各种含义，以及它们的无毒盐和含有它们的药物组合物。这些新型化合物对治疗高血压和充血性心力衰竭等疾病具有价值。该发明还涉及新型化合物的制备过程以及化合物在医学治疗中的应用。
• Pyridine compounds which have useful pharmaceutical utility
  申请人：Imperial Chemical Industries PLC

  公开号：US05380730A1

  公开（公告）日：1995-01-10

  The invention concerns pharmaceutically useful compounds of the formula I, in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, X and Z have the various meanings defined herein, and their non-toxic salts, and pharmaceutical compositions containing them. The novel compounds are of value in treating conditions such as hypertension and congestive heart failure. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.

  本发明涉及公式I的具有药用价值的化合物，其中R.sup.1，R.sup.2，R.sup.3，R.sup.4，R.sup.5，R.sup.6，R.sup.7，X和Z具有在此定义的各种含义，以及它们的非毒性盐和含有它们的药物组合物。这些新型化合物对于治疗高血压和充血性心力衰竭等疾病具有价值。本发明还涉及制造新型化合物的工艺以及在医疗治疗中使用这些化合物的方法。
• Pyridine compounds which are useful as angiotensin II receptor
  申请人：Imperial Chemical Industries PLC

  公开号：US05236936A1

  公开（公告）日：1993-08-17

  The invention concerns pharmaceutically useful compounds of the formula I, in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, X and Z have the various meanings defined herein, and their non-toxic salts, and pharmaceutical compositions containing them. The novel compounds are of value in treating conditions such as hypertension and congestive heart failure. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.

  该发明涉及公式I的药用化合物，其中R.sup.1，R.sup.2，R.sup.3，R.sup.4，R.sup.5，R.sup.6，R.sup.7，X和Z具有本文所定义的各种含义，以及它们的非毒性盐和含有它们的制药组合物。这些新型化合物在治疗高血压和充血性心力衰竭等疾病方面具有价值。该发明还涉及新型化合物的制造过程以及化合物在医疗治疗中的应用。
• Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors
  申请人：Gupta Ramesh Chandra

  公开号：US20100010035A1

  公开（公告）日：2010-01-14

  The present invention relates to new compounds of the formula [Chemical formula should be inserted here. Please see paper copy] wherein R1, R2, R3, and R31 are as specified herein. The invention also relates to a method for preparation thereof, as well as combinations of the new compounds with previously known agents. The invention also relates to the use of the above-mentioned compounds and combinations for the preparation of a medicament for treating hypertension of different kinds, alleviating organ damage of different kinds, treating or preventing diabetic nephropathy, treating endothelin and angiotensin mediated disorders, and treating prostate cancer.

  本发明涉及一种新的化合物，其化学式为[应在此处插入化学式。请参见纸质副本]，其中R1、R2、R3和R31如本文所述。本发明还涉及一种制备该化合物的方法，以及新化合物与先前已知药剂的组合。本发明还涉及上述化合物和组合物的用途，用于制备治疗不同类型的高血压、缓解不同类型的器官损伤、治疗或预防糖尿病肾病、治疗内皮素和血管紧张素介导的疾病以及治疗前列腺癌的药物。